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Introduction
The use of extracorporeal circulatory assist devices 
requires effective anticoagulation due to proinflamma-
tory and prothrombotic responses caused by blood 
interacting with the non-endothelial surfaces of the 
circuit.1 In ECMO, additionally, the membranes of an 
oxygenator provide an increased non-biocompatable 
surface area. Therefore, anticoagulation is needed to 
prevent thrombosis of the cannulae, oxygenator and 
circuit tubing,2 i.e. to prevent life-threatening throm-
bosis while excessively bleeding should be avoided.1 
On the other hand, effective anticoagulation is associ-
ated with an increased bleeding tendency.
Decreased maximum clot firmness  
in rotational thromboelastometry  
(ROTEM®) is associated with bleeding during 
extracorporeal mechanical circulatory support
Antti Laine,1 Tomi Niemi,1 Raili Suojaranta-Ylinen,2  
Peter Raivio,3 Leena Soininen,2 Karl Lemström,3  
Pekka Hämmäinen3 and Alexey Schramko1,2 
Abstract
Background: We aimed to characterize the coagulation disturbances which may increase the risk of bleeding, 
thrombosis or death shortly after implantation of an extracorporeal membrane oxygenation (ECMO) or ventricular 
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Additionally, conventional laboratory testing, rotational thromboelastometry (ROTEM) and platelet function analysis 
(Multiplate) were performed at predetermined intervals.
Results: Four out of twenty-four (16.7%) of ECMO patients and 6/23 (26.1%) of VAD patients had severe bleeding 
after the procedure. When all the patients were analyzed together, low maximum clot firmness (MCF) in ExTEM and 
FibTEM analyses was associated with severe bleeding (p<0.05) and low MCF in FibTEM with 30-day mortality. Low 
platelet count and hematocrit levels were also associated with severe bleeding. When VAD and ECMO patients were 
separated into different groups, the association between ROTEM parameters, bleeding and survival was found only 
in limited time points.
Four patients with VAD had cerebral ischemia indicative of thromboembolism. However, this had no significant cor-
relation with ROTEM or Multiplate parameters.
Conclusion: Hypocoagulation shown by ROTEM was associated with bleeding complications in patients with mechanical 
circulatory support. In contrast, hypercoagulation did not correlate with clinical thrombosis.
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Anticoagulation treatment is challenging as there are 
often underlying coagulation disorders of various rea-
sons in these critically ill patients. Anticoagulation usu-
ally gets more and more challenging with the duration 
of extracorporeal circulation3 and unidentified minor 
clots can cause a variety of thromboembolic events, 
even in patients considered adequately anticoagulated.4,5
The earliest and still the predominant test to moni-
tor heparin anticoagulation for extracorporeal circula-
tion devices is the activated clotting time (ACT) which 
measures the integrity of the intrinsic and common 
coagulation pathways.6–8 However, the ACT’s ability to 
provide adequate anticoagulation is limited because the 
accuracy of the test is influenced by multiple variabili-
ties, such as coagulopathy, oral anticoagulants, hypofi-
brinogenemia, thrombocytopenia, platelet dysfunction 
or inhibition, antithrombin III (ATIII) level, hypother-
mia, patient age and hemodilution.9 Also, numerous 
technical factors, e.g. sample size or temperature can 
affect the test results.8
The activated partial thromboplastin time (aPTT) is 
universally recognized as a standard monitor for hepa-
rin therapy, except when high heparin dosing is required, 
as in cardiopulmonary bypass. However, the aPTT has 
also several limitations. For example, it recognizes nei-
ther fibrinolysis nor disturbance of clot formation. Due 
to these limitations, using ROTEM during evaluation 
of coagulation status could give additional information 
to the use of ACT and aPTT alone.
Various easily and quickly obtainable point-of-care 
(POC) coagulation monitoring tests are applicable 
in monitoring anticoagulation during mechanical circu-
latory support. Whole blood viscoelastic tests, such 
as rotational thromboelastometry or thromboelastog-
raphy, describe the entire whole blood coagulation 
process, including clot initiation, formation and stabili-
zation, as well as fibrinolysis. The addition of platelet 
function analyses to the monitoring palette provides 
information about platelet function.
The objective of the current study was to character-
ize coagulation disturbances in combination with 
bleeding or thromboembolic complications using POC 
methods in addition to conventional laboratory hemo-
static testing.
Methods
After approval of the Ethics Committee for Surgery in 
Helsinki University Hospital (372/E6/07), we prospec-
tively studied consecutive patients requiring an extra-
corporeal circulation assist device between March 2008 
and June 2012 at the Department of Cardiac Surgery in 
Helsinki University Hospital, Helsinki, Finland.
The indications for mechanical circulatory support 
were cardiac failure or severe respiratory failure (Table 
1). The types of devices were ECMO (Bioconsole 560, 
Medtronic, Minneapolis, Minnesota USA or 
Rotaflow, MAQUET Holding B.V. & Co., Rastatt, 
Germany) or VAD (Berlin Heart Excor, Berlin Heart 
GmbH, Berlin, Germany). The use of mechanical cir-
culatory support was started after the decision of the 
multidisciplinary team of cardiologists, cardiac sur-
geons and anesthesiologists. Some of ECMOs were 
cannulated percutaneously (48% (n=11) in the ECMO 
group), other devices surgically centrally (22% (n=5) 
in the ECMO group). The cannulation procedures 
were performed either electively or urgently, as 
required. Patients were connected to ECMO by can-
nulas sized: v. femoralis 21-27 Fr, a. femoralis 15-21 
Fr or, when centrally cannulated, aorta 20-22 Fr and 
vena cava 28-34 Fr. In veno-venous ECMO, Avalon 
cannulas 27-31 Fr in size were used. Flow ranges in 
veno-arterial ECMO were 2.0-2.4 l/min/m2 and in 
veno-venous ECMO 1.5-2.0 l/min/m2. The duration of 
ECMO treatment ranged from 3 – 30 days.
The patient’s neurological status was assessed clini-
cally and with computed tomography scan, if necessary, 
during the 30-day follow-up period at the daily sedation 
breaks. Sedation breaks were not executed if the patient 
had an open sternotomy wound or central cannulation. 
Severe bleeding was defined as two or more liters during 
the 24 hours following surgery or the patient receiving 
more than five units of packed red blood cells (RBC) in 
24 hours.10 A thrombotic complication was defined as a 
venous or arterial thromboembolism leading to neuro-
logical complication or pulmonary embolism. Mortality 
was assessed at 30 days after the start of mechanical cir-
culatory support.
Anticoagulation protocol
Anticoagulation was started within 24-36 hours after 
the initiation of extracorporeal circulatory support. If 
implantation/cannulation of the device was done sur-
gically, anticoagulation was not started until postop-
erative bleeding had ceased. Unfractioned heparin 
was used as anticoagulant. Heparin was diluted in 
normal saline, with an heparin concentration of 100 
U/mL, and administered as a continuous infusion 
without loading bolus, starting with 200-300 U/h. 
ACT and aPTT were measured before the start of the 
anticoagulation regimen and were then performed 
every 4 hours (ACT) or 6 hours (aPTT). The activity 
of AT III was measured daily. The heparin infusion 
rate was increased slowly to achieve and maintain 
both ACT and aPTT at the target levels. Hemoglobin 
(Hb) concentration was kept above 9.0-10.0 g/dL and 
the platelet count (PLC) above 50 x109/L or, with 
evidence or suspicion of bleeding, above 100 x109/L. 
The targets of ACT and aPTT were set according to 
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hospital practices: if the PLC was under 100 x109/L, 
the target of the ACT was set to 160 – 180 sec and the 
aPTT to 50 – 60 sec. If the PLC was over 100 x109/L, 
the targets were 180 – 200 sec and 60 – 70 sec, respec-
tively. The target AT III activity was over 50%. Pooled 
human plasma (Octaplas, Octapharma AB, 
Stockholm, Sweden) or AT III concentrate (Atenativ, 
Octapharma AB) was administered if the AT III activ-
ity decreased under 50%.
The study period was seven days after the start of 
the mechanical circulatory support. Blood product 
transfusions, urine output, postoperative bleeding and 
net fluid balance were registered daily with PI Client 
Information System (Caresuite 8.2, PICIS Inc., San 
Fransisco, CA, USA). Laboratory tests, including Hb 
(g/dL), hematocrit (Hct, %), PLC, (x 10 9/L), C-reactive 
protein (CRP), prothrombin time value (TT, %), inter-
national normalized ratio (INR), lactate concentra-
tion, AT III (%), anti-FXa (U/mL) and ROTEM 
(ROTEM, TEM International, Munich, Germany) 
(ExTEM [tissue factor activator to assess the external 
coagulation pathway] + FibTEM [ExTEM based assay 
for fibrinogen part of coagulation, platelet activity 
blocked with cytochalasin D] activators) were per-
formed preoperatively (within 24 hours before device 
installation) and daily for seven days postoperatively. 
Platelet function analysis with a Multiplatedevice 
(Multiplate, Dynabyte Medical, Munich, Germany) 
using TRAPtest (Thrombin Receptor Activating 
Peptide-6), ADPtest (Adenosine Diphosphate) and 
ASPItest (to assess Aspirin, Acetylsalicylic acid effect) 
activators was performed preoperatively and on post-
operative days (POD) 1, 3, 5 and 7.
Statistics
The differences were analyzed with the non-parametric 
repeated measures analysis of variance (Kruskal-Wallis 
test). Correlations were tested with the Spearman test. 
The Mann-Whitney U-test was used for paired com-
parisons. Since the data were mostly not normally dis-
tributed (Kolmogorov-Smirnov test), the results are 
shown as medians (Interquartile range, IQR). A p-value 
<0.05 was considered to be statistically significant.
Table 1. Background information of the patient population.
VAD (n=24) ECMO (n=23)
Male 20 15
Female 4 8
Age (median (IQR)) 51.5 (12) 54.0 (20)
Cannulation  
 Surgical 24 (100%) 12 (52.2%)
 Percutaneous n/a 11 (47.8%)
CRRT 9 (37.5%) 6 (26.1%)
30-day mortality 33.3% (n=8) 30.4% (n=7)
Anamnesis  
 Previously healthy – 17.4% (n=4)
 Ischemic heart disease 50.0% (n=12) 21.7% (n=5)
 Other cardiac condition (congenital/acquired) 70.8% (n=17) 39.1% (n=9)
 Pulmonary disease (chronic) – 17.4% (n=4)
 Diabetes (type1/2) 25.0% (n=6) 8.7% (n=2)
 Hypertension 25.0% (n=6) 4.3% (n=1)
 Chronic kidney disease 12.5% (n=3) 8.7% (n=2)
 Other condition not listed above 12.5% (n=3) 8.7% (n=2)
Indication  
 Cardiac surgery requiring CPB – 26.1% (n=6)
 Dilated cardiomyopathy 41.7% (n=10) 8.7% (n=2)
 Acute myocardial infarction (cardiogenic shock) 25.0% (n=6) 8.7% (n=2)
 Cardiac failure/cardiogenic shock of other ethiology 29.2% (n=7) 4.3% (n=1)
 Myocarditis – 8.7% (n=2)
 Impaired oxygenation/respiratory failure – 13.0% (n=3)
 Pulmonary artery hypertension – 4.3% (n=1)
 Pneumonia – 13.0% (n=3)
 Complications of pulmonary/cardiac transplantation 4.2% (n=1) 13.0% (n=3)
VAD: ventricular assist device; ECMO: extracorporeal membrane oxygenation; IQR: interquartile range; CRRT: continuous renal replacement 
therapy; CBP: cardiopulmonary bypass.
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Results
Forty-seven patients were enrolled in this study. Overall, 
forty-five patients (23 treated with ECMO, 24 with 
VAD; of which 16 LVAD and 8 BiVAD) were analyzed. 
Two patients were first treated (2 and 7 days respec-
tively) with veno-arterial ECMO before a VAD was 
implanted. The total duration of treatment for each 
patient in the VAD group was more than 7 days; in the 
ECMO group 14 patients were treated for more than 7 
days, 1 for 6 days, 4 for 5 days, 3 for 4 days and 1 for 3 
days. The median age was 54.0 (IQR 20) in the ECMO 
group and 51.5 (IQR 12.2) in the VAD group. Descriptive 
statistics of all patients are presented in Table 1.
Indications for extracorporeal circulatory support 
were acute cardiac failure (n=42) or respiratory failure 
(n=5). One patient had ECMO installed after drowning. 
Five ECMOs were veno-venous and eighteen veno-arte-
rial. The results of the conventional coagulation tests 
and CRP during the study period are shown in Table 2.
Twelve patients, four in the VAD group (16.7%) and 
six in the ECMO group (26.1%), had severe bleeding 
postoperatively, either from cannulae insertion sites or 
from postoperative chest tube drains. When all the 
patients were analyzed together, the median ExTEM 
MCF (63.0 mm (IQR 8 mm) vs. 52.0 mm (IQR 27 mm), 
p=0.032) and FibTEM MCF (26.0 mm (IQR 17 mm) vs. 
11.0 mm (IQR 14 mm), p=0.011) were preoperatively 
significantly higher in patients without severe postop-
erative bleeding than in those patients with severe 
bleeding. ExTEM MCF on POD 1 (51.5 mm (IQR 9 
mm) vs. 61.0 mm (9 mm), p=0.018) and on PODs 6 
(53.0 mm (IQR 9 mm) vs. 64.5 mm (12 mm), p=0.011) 
and 7 (57.5 mm (IQR 11 mm) vs. 67 mm (11 mm), 
p=0.011) were significantly lower in the patients with 
severe postoperative bleeding than in those without 
bleeding. On the other hand, FibTEM MCF showed sig-
nificant difference only on POD 1 (9.5 mm (IQR 9 mm) 
vs. 19.0 mm (13 mm), p=0.024).
FibTEM MCF on POD 6 was significantly higher in 
recovered patients than in non-survivals (25.0 mm (IQR 
15 mm) vs. 19 mm (7 mm), p=0.024) (Figure 1). This 
was also seen in VAD patients (p=0.016) when analyzed 
separately, but not in ECMO patients. ExTEM MCF had 
a tendency to differ between survivals and non-surviv-
als: in the survival group, it did not change during the 
observation time and stayed on the preoperative level, 
p>0.05. In the non-survivals, ExTEM MCF had a trend 
of decreasing compared to recovered patients, although 
the finding was not statistically significant (Figure 2). 
The platelet count was significantly lower in patients 
with severe postoperative bleeding. This was displayed 
preoperatively (119 x 109/L (IQR 105 x 109/L) vs. 153 x 
109/L (111 x 109/L), p=0.024) and on PODs 5 (61 x 109/L 
(48 x 10 9/L) vs. 110.5 x 109/L (61 x 109/L), p=0.012), 6 
(78 x 109/L (59 x 109/L) vs. 132 x 109/L (86 x 109/L), 
p=0.009) and 7 (95.5 x 109/L (62 x 109/L) vs. 146 x 109/L 
(102 x 109/L), p=0.017). The hematocrit was significantly 
Table 2. Median conventional laboratory test values during the study period.
aPTT 
(sec)
TT (%) Anti-Fxa 
(U/mL)
INR AT III 
(%)
CRP 
(mg/L)
PLC 
(x109/L)
Hct (%) 
 (23 – 33 
sec)
(70 – 130 
%)
(84 – 
108 %)
(< 3mg/L) (150 – 360 
x109/L)
(35-46 (men), 
39-50 (women))
VAD 
patients
 
 
 
 
  
 
Pre-op. 33.0 (19) 47.0 (21) 0.185 (0.20) 1.4 (0.7) 58.0 (36) 36.0 (64) 156.0 (114) 32.0 (7)
POD 1 33.0 (8) 47.5 (21) 0.100 (0.00) 1.5 (0.5) 52.0 (25) 68.0 (64) 132.5 (66) 31.0 (3)
POD 2 37.0 (11) 51.0 (27) 0.100 (0.00) 1.5 (0.4) 55.0 (30) 154.0 (101) 111.0 (45) 31.0 (3)
POD 3 41.5 (20) 62.0 (37) 0.100 (0.00) 1.3 (0.0) 61.0 (26) 163.0 (105) 107.5 (67) 31.0 (4)
POD 4 46.0 (24) 69.0 (31) 0.100 (0.20) 1.3 (0.2) 64.0 (25) 141.0 (86) 112.0 (85) 31.0 (3)
POD 5 44.0 (21) 68.0 (16) 0.140 (0.20) 1.3 (0.2) 67.5 (28) 114.5 (90) 114.5 (67) 31.0 (3)
POD 6 47.0 (18) 66.0 (32) 0.240 (0.34) 1.3 (0.4) 71.0 (33) 115.0 (94) 134.0 (80) 30.0 (3)
POD 7 46.0 (29) 58.5 (37) 0.250 (0.21) 1.4 (0.4) 78.0 (28) 104.0 (99) 157.5 (116) 30.0 (3)
ECMO 
patients
 
 
 
  
 
 
Pre-op. 39.0 (35) 49.5 (22) 0.180 (0.10) 1.4 (0.6) 67.0 (29) 112.5 (176) 130.0 (108) 30.0 (4)
POD 1 39.5 (52) 53.5 (48) 0.100 (0.10) 1.4 (0.4) 54.5 (26) 85.0 (124) 114.0 (47) 30.0 (2)
POD 2 47.0 (19) 57.0 (40) 0.215 (0.30) 1.4 (0.6) 61.0 (28) 123.0 (163) 87.0 (59) 30.0 (3)
POD 3 51.0 (19) 80.0 (65) 0.120 (0.20) 1.2 (1.0) 65.0 (16) 125.0 (230) 87.0 (29) 29.0 (3)
POD 4 51.0 (17) 100.0 (57) 0.230 (0.30) 1.2 (0.4) 73.0 (24) 110.5 (214) 93.0 (48) 29.0 (3)
POD 5 47.0 (19) 102.5 (41) 0.325 (0.37) 1.1 (0.6) 70.0 (24) 111.0 (181) 99.0 (55) 30.0 (2)
POD 6 45.0 (14) 116.0 (28) 0.260 (0.42) 1.1 (0.1) 83.0 (21) 102.0 (131) 90.0 (52) 30.0 (3)
POD 7 46.0 (15) 118.0 (39) 0.320 (0.24) 1.1 (0.2) 76.5 (18) 105.0 (223) 95.5 (65) 30.0 (3)
Values are medians (interquartile range in parenthesis).
aPTT: activated partial thromboplastin time; Anti-Fxa: anti Factor Xa; TT: thromboplastin time; INR: international normalized ratio; AT III: 
antithrombin III; CRP: C-reactive protein; PLC: platelet count; Hct: hematocrit; POD: postoperative day.
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lower on PODs 5 and 6 in patients with severe bleeding. 
Neither the thromboplastin time nor the aPTT were 
associated with bleeding in this patient population.
Analysis of separated groups
In the VAD group, there were no significant findings in 
ExTEM MCF and FibTEM MCF preoperatively in patients 
with bleeding or thrombotic complications. On POD 6, 
both ExTEM and FibTEM MCF were significantly lower 
in patients with bleeding complications (p=0.043 and 
p=0.014, respectively) (Table 3). FibTEM MCF on POD 6 
was significantly higher in recovered patients (26 mm vs. 
20 mm, p=0.016). In the ECMO group, there were no 
thrombotic complications. In the ECMO patients, ExTEM 
MCF was significantly lower on POD 1 (p=0.045) and 
FibTEM MCF was already preoperatively significantly 
lower (p=0.019) in patients with bleeding complications 
(Table 3). There was no correlation between survival and 
ExTEM or FibTEM MCF in either of the study groups 
when analyzed separately. The median ExTEM and 
FibTEM MCF values in both groups are presented in 
Table 4. The platelet counts on POD 5 (86.5 x 109/L (37 x 
109/L) vs. 121 x 109/L (63 x 109/L), p=0.020) and 6 (88.5 x 
109/L (53 x 109/L) vs. 149.5 x 109/L (66 x 109/L), p=0.044) 
were significantly lower in VAD patients with severe 
bleeding. The PLC was also significantly lower in ECMO 
patients with severe bleeding on PODs 5 (51 x 109/L (50 x 
109/L) vs. 100 x 109/L (30 x 109/L), p=0.041) and 6 (54 x 
109/L (74 x 109/L) vs. 107 x 109/L (50 x 109/L), p=0.037). 
The aPTT on POD 3 was significantly lower in patients 
with bleeding (40 sec vs. 41.5 sec, p=0.012).
Multiplate analyses did not show any significant 
correlation with bleeding, thrombosis or survival in 
either group. Values are presented in Table 5. Fluid bal-
ance did not show any significant correlation with 
ROTEM parameters.
The mortality rate at 30 days was 30.4% in the ECMO 
group and 37.5% in the VAD group. In both groups, 
slightly more negative fluid balance was associated with 
better survival, but this finding was not statistically sig-
nificant except in the ECMO group on POD 3 (-583 ml 
(IQR 1073 ml) vs. +630 ml (IQR 1161 ml), p=0.033). 
Median net fluid balance in survivors and non-survi-
vors is presented in Figures 3 and 4. Six patients (26.1%) 
in the ECMO group and nine patients (37.5%) in the 
VAD group needed continuous renal replacement ther-
apy during the study period. Additionally, decreased 
amount of platelets on POD 4 and 5 in the VAD group 
correlated positively with mortality.
Four patients with VAD (16.7%) and no patients with 
ECMO had neurological complications (for this study, 
defined as intracranial hemorrhage or ischemia). Two of 
them had a transient ischemic attack and two had a 
stroke. Both patients with a stroke died. There was no 
significant correlation between ROTEM or Multiplate 
parameters and neurological complications.
Discussion
In this study, we showed that low ExTEM and FibTEM 
maximum clot firmness in ROTEM analysis was 
associated with a bleeding tendency in patients 
treated with extracorporeal circulatory support. 
Bleeding complications are often encountered during 
Figure 1. Median maximum clot firmness in FibTEM.
CI: confidence interval; MCF: maximum clot firmness;  
POD: postoperative day.
Figure 2. Median maximum clot firmness in ExTEM.
CI: confidence interval; MCF: maximum clot firmness;  
POD: postoperative day.
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extracorporeal circulation and they are a major cause 
of morbidity and mortality. Surgical site bleeding 
is reported in 6-32% of cases11 and intracranial 
hemorrhage, the most devastating and potentially 
life-threatening complication, occurs in up to 3-19% 
of patients.12,13 In our study group, severe bleeding 
was observed in 21% of the patients, but none died 
from this complication. There were no intracranial 
Table 3. Median ExTEM and FibTEM MCF in VAD and ECMO groups. Patients with bleeding complications are shown separately.
VAD ECMO 
 No bleeding 
complications
Bleeding 
complications
P-value No bleeding 
complications
Bleeding 
complications
P-value
 Median (IQR) Median (IQR) Median (IQR) Median (IQR)
ExTEM MCF 
(mm)
Pre-op. 64.5 (16) 48.5 0.24 63.0 (11) 52.0 (22) 0.09
(Reference range 
50-72 mm)
POD 1 60.0 (14) 51.5 (11) 0.23 61.0 (7) 52.0 (10) 0.045
POD 2 64.0 (13) 55.0 (27) 0.16 61.5 (9) 53.0 (13) 0.23
POD 3 59.0 (11) 54.5 (15) 0.19 60.0 (9) 52.5 (20) 0.19
POD 4 62.5 (12) 53.0 0.12 59.0 (11) 57.0 0.81
POD 5 64.0 (14) 57.5 0.33 63.0 (11) 54.0 0.14
POD 6 65.0 (12) 56.0 0.043 59.0 (11) 18.0 0.23
POD 7 67.0 (10) 63.0 0.11 66.0 (16) 54.0 0.07
FibTEM MCF 
(mm)
Pre-op. 15.5 (5) 10.0 1.00 31.0 (8) 11.0 (12) 0.019
(Reference range 
9-25 mm)
POD 1 16.5 (12) 9.5 (8) 0.10 19.0 (14) 11.5 (9) 0.09
POD 2 20.0 (10) 11.5 (10) 0.05 17.5 (10) 16.0 (4) 0.47
POD 3 22.0 (13) 16.5 (14) 0.19 22.0 (9) 18.0 (13) 0.51
POD 4 23.0 (14) 17.0 0.16 23.5 (8) 19.5 0.60
POD 5 23.0 (14) 23.0 0.55 22.0 (17) 21.0 0.38
POD 6 24.0 (9) 18.0 0.014 19.0 (16) 25.5 0.77
POD 7 28.0 (10) 21.0 0.06 25.0 (14) 20.0 0.91
Interquartile range (IQR) provided when applicable. Statistically significant differences highlighted in Bold. VAD: ventricular assist device; ECMO: 
extracorporeal membrane oxygenation; MCF: maximum clot firmness; POD: postoperative day.
Table 4. Median ExTEM and FibTEM in VAD and ECMO groups.
VAD ECMO
 Median (IQR) Median (IQR)
ExTEM MCF (mm) Preop. 64.5 (16) 48.5
(Reference range 50-72 mm) POD 1 60.0 (14) 51.5 (11)
 POD 2 64.0 (13) 55.0 (27)
 POD 3 59.0 (11) 54.5 (15)
 POD 4 62.5 (12) 53.0
 POD 5 64.0 (14) 57.5
 POD 6 65.0 (12) 56.0
 POD 7 67.0 (10) 63.0
FibTEM MCF (mm) Preop. 15.5 (5) 10.0
(Reference range 9-25 mm) POD 1 16.5 (12) 9.5 (8)
 POD 2 20.0 (10) 11.5 (10)
 POD 3 22.0 (13) 16.5 (14)
 POD 4 23.0 (14) 17.0
 POD 5 23.0 (14) 23.0
 POD 6 24.0 (9) 18.0
 POD 7 28.0 (10) 21.0
Interquartile range (IQR) provided when applicable. VAD: ventricular assist device; ECMO: extracorporeal membrane oxygenation; MCF: maximum 
clot firmness; POD: postoperative day.
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bleeding complications; central nervous system com-
plications were limited to ischemic events.
In conventional laboratory tests, such as ACT and 
aPTT, we saw, preoperatively, signs of underlying clot-
ting disorders. This relates mostly to the severe and 
chronic illness from which the patients are suffering, as 
well as previous surgery with blood and coagulation fac-
tor loss and transfusions. Liver congestion due to heart 
failure often leads to the underproduction of coagulation 
factors and chronic illness, itself, together with repeated 
laboratory testing can drive the patients to anemia. Also, 
in the postoperative state, there is usually some hypoco-
agulation present due to the acute consumption of coag-
ulation factors caused by the surgery. Extracorporeal 
circulation associates strongly with acquired coagulation 
deficiencies, such as factor XIII deficiency, von 
Willebrand syndrome and thrombocytopenia, as early as 
during the first week of treatment.14 The low platelet 
count predictably was associated with bleeding compli-
cations. The crucial role of platelets for postoperative 
Table 5. Median Multiplate values in VAD and ECMO groups.
VAD ECMO
 Median (IQR) Median (IQR)
TrapTest (AUC) Preop. 73.0 (59) 86.0 (79)
(Reference range 94-156) POD 1 92.0 (53) 55.0 (58)
 POD 3 84.0 (37) 72.0 (34)
 POD 5 75.5 (32) 61.0 (42)
 POD 7 77.0 (36) 63.0 (46)
AspiTest (AUC) Preop. 48.5 (32) 16.0 (22)
(Reference range 75-136) POD 1 49.0 (49) 14.0 (18)
 POD 3 48.0 (25) 16.0 (36)
 POD 5 42.0 (51) 23.0 (18)
 POD 7 50.0 (36) 34.5 (35)
AdpTest (AUC) Preop. 50.5 (32) 21.0 (43)
(Reference range 53-122) POD 1 34.0 (38) 22.5 (29)
 POD 3 47.0 (32) 20.0 (40)
 POD 5 37.0 (43) 22.0 (21)
 POD 7 43.0 (21) 33.0 (22)
AUC: area under the curve; VAD: ventricular assist device; ECMO: extracorporeal membrane oxygenation; IQR: interquartile range; POD: 
postoperative day.
Figure 4. Median fluid balance in the ECMO group. ECMO: 
extracorporeal membrane oxygenator; CI: confidence interval; 
POD: postoperative day. * statistically significant (p=0.033).
Figure 3. Median fluid balance in the VAD group.
VAD: ventricular assist device; CI: confidence interval;  
POD: postoperative day.
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bleeding, especially after cardiac surgery, has been dem-
onstrated previously.15,16 In this study, we were unable to 
show any significant association between Multiplate 
parameters and outcome results. This most probably has 
to do with the relatively small number of patients, as 
platelet function analysis has previously been shown to 
correlate with bleeding tendency in cardiac surgery.17
MCF in ExTEM and FibTEM was associated with 
30-day survival in ECMO and VAD patients. This was 
seen very early in the 7-day study period. In survivors, 
MCF in ExTEM remained almost unchanged while MCF 
in FibTEM was significantly higher in the last days of the 
study period. As many extracorporeal life support 
patients die from multi-organ failure, the problems with 
coagulation factor production, possibly associated with 
decreased liver function, can be seen in viscoelastic 
blood analysis in the early phase, although, when the 
VAD and ECMO groups were analyzed separately, the 
statistical significance of this finding diminished. This 
has to do with the fact that the number of patients in this 
study was limited and not enough to demonstrate statis-
tical difference. Thirty-day mortality in our study groups 
(30% in the ECMO group and 38% in the VAD group) 
was relatively low compared to previous studies, indicat-
ing in-hospital mortality rates between 24-90%.18 As rec-
ognized in numerous previous studies,19–21 negative fluid 
balance correlated with better survival; in our study, we 
could demonstrate only a tendency for this. About 30% 
of all our patients needed renal replacement therapy dur-
ing extracorporeal life support, which is less than in pre-
vious reports.22 Despite extracorporeal ultrafiltration, 
some patients were still unable to maintain negative fluid 
balance, leading to complications and even death. The 
dilution of coagulation factors in patients with a positive 
fluid balance could expose patients to bleeding. Non-
survivors also seem to be unable to recover from throm-
bocytopenia caused by bone marrow suppression and by 
the use of extracorporeal circulation.23
Generally speaking, ROTEM analyses could have an 
effect on guiding the treatment choices in these patients, 
e.g. when choosing transfusions of blood products ver-
sus coagulation factor concentrates. The reduction of 
blood product use in VAD patients when using POC 
hemostasis monitoring was shown in a retrospective 
analysis by Sun et al.24 In our institution, this method is 
still not fully established, but has proven to be an effec-
tive additional tool, especially in complex major surgery. 
Getting the blood analysis results promptly and bedside 
is a present-day method of testing coagulation in both 
the intensive care unit and the operating room. Whole 
blood viscoelastic tests also reflect the coagulation status 
in a way that no conventional laboratory test is able 
to do; it shows clot propagation, formation, and stabili-
zation dynamically; additionally, it demonstrates the 
presence of fibrinolysis better than any laboratory analy-
sis, e.g. fibrinogen d-dimer is always elevated in this 
patient group as an acute phase protein. Previous studies 
showed that whole blood analysis provides more accu-
rate information of the coagulation process in vivo.25,26
There are several limitations in our study. First, the 
patient number is limited due to scarcity of critically ill 
patients requiring extracorporeal circulatory support. 
Analyzing VAD and ECMO patients together has its 
limitations due to some crucial differences between the 
systems but, in our opinion, is, in part, justified based 
on numerous similarities of the two systems: the 
patients’ blood moves continuously through tubes with 
non-biocompatible surfaces. Secondly, there are numer-
ous confounding factors that have to be considered 
when generalizing the results: surgical bleeding versus 
bleeding caused by deficiency in coagulation factors 
cannot be compared, especially when considering 
thromboelastometry.
Whether the additional information provided by 
these POC tests could actually assist with the decision-
making in anticoagulation and transfusion therapy in 
ECMO and VAD patients has to be studied in a rand-
omized, prospective arrangement.
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